Clinical trial
Randomized, Double-Blind, Placebo-Controlled, Safety and Tolerability Study of Escalating Single Doses of ITI-214 in Patients With Systolic Heart Failure
NCT03387215 is registered in ClinicalTrials.gov with Intra-Cellular Therapies, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Randomized, Double-Blind, Placebo-Controlled, Safety and Tolerability Study of Escalating Single Doses of ITI-214 in Patients With Systolic Heart Failure
- Lead sponsor
- Intra-Cellular Therapies, Inc.
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- July 10, 2018
- Completion date
- March 16, 2020
- Enrollment
- 36 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.